EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris: a population-based retrospective cohort study

Yijia Liu, Zhu Li, Xu Wang, Tongyao Ni, Mei Ma, Yuanyuan He, Rongrong Yang, Mingchi Luo

Acupuncture and Herbal Medicine · 2022

DOI: 10.1097/hm9.0000000000000028 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Acupuncture and Herbal Medicine, 2022. Verfasst von Yijia Liu und 7 weiteren Autor:innen. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to explore the effects of Chinese patent medicine (CPM) in reducing the incidence of major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD) angina pectoris and improving clinical effectiveness and provide evidence for its use as clinical adjuvant therapy.

Methods

Twenty-eight thousand five hundred and seventeen patients hospitalized with CHD angina pectoris from 6 hospitals were divided into CPM group ( n = 11,374) and non-CPM group ( n = 17,143) to evaluate the incidence of MACE, including myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting.

Results

The incidence of MACE in the CPM group was lower than that in the non-CPM group. CPM therapy was an independent protective factor that reduced the overall risk of MACE [adjusted hazard ratio = 0.40, 95% confidence interval (0.33; 0.49)]. Patients in the CPM group who received one, two, or three types of CPM could benefit from adjuvant treatment with CPM, and taking more types of CPM was associated with a lower risk of MACE. In addition, the male population was better than the female population in taking CPM, and middle-aged people aged 55 to 64 were more suited to take CPM based on Western medicine.

Conclusions

The use of CPM as adjuvant therapy can decrease the occurrence of MACE in patients with CHD angina pectoris, especially in men and middle-aged people, and the drug treatment plan should be optimized accordingly. However, this conclusion needs further verification by prospective cohort studies in the future.

Zitieren

APA

Liu, Y., Li, Z., Wang, X., Ni, T., Ma, M., He, Y., Yang, R., & Luo, M. (2022). Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris: a population-based retrospective cohort study. Acupuncture and Herbal Medicine. https://doi.org/10.1097/hm9.0000000000000028

Vancouver

Liu Y, Li Z, Wang X, Ni T, Ma M, He Y, et al. Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris: a population-based retrospective cohort study. Acupuncture and Herbal Medicine. 2022. doi:10.1097/hm9.0000000000000028

BibTeX
@article{Liu2022,
  author = {Liu, Yijia and Li, Zhu and Wang, Xu and Ni, Tongyao and Ma, Mei and He, Yuanyuan and Yang, Rongrong and Luo, Mingchi},
  title = {Effects of adjuvant Chinese patent medicine therapy on major adverse cardiovascular events in patients with coronary heart disease angina pectoris: a population-based retrospective cohort study},
  journal = {Acupuncture and Herbal Medicine},
  year = {2022},
  doi = {10.1097/hm9.0000000000000028}
}
Kostenlos starten →